What is Epitopix?
Epitopix is dedicated to the advancement of animal health through innovative vaccine solutions. The company focuses on developing, manufacturing, and distributing cutting-edge veterinary vaccines designed to bolster the health and performance of food animals. Leveraging proprietary technologies, Epitopix creates both licensed and custom-made vaccines targeting specific bacterial and viral pathogens in poultry, bovine, and swine populations. Their commitment lies in disease prevention and enhancing livestock productivity through sophisticated vaccine science.
How much funding has Epitopix raised?
Epitopix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Epitopix
PPP
Public-Private Partnership
What's next for Epitopix?
With the recent influx of capital and its designation as a large-scale late-stage funding recipient, Epitopix is strategically positioned for accelerated growth and market expansion. This significant investment is likely to fuel further research and development initiatives, enhance manufacturing capabilities, and broaden the company's commercial reach. The strategic nature of the recent financing suggests potential collaborations or market entries aimed at solidifying Epitopix's leadership in the global veterinary vaccine market and addressing critical needs in animal disease prevention.
See full Epitopix company page
